Drug intelligence / Profile preview

CKD-344

Development stage: Phase 1
Lead developer: Chong Kun Dang Pharmaceutical
Modality: Small Molecules

Overview

CKD-344 is an investigational small molecule anticoagulant developed by Chong Kun Dang Pharmaceutical. It acts as a direct inhibitor of factor Xa, a key enzyme in the coagulation cascade responsible for thrombin generation and blood clot formation. The drug is being evaluated primarily for its safety and pharmacokinetics in healthy adult volunteers and has not yet received regulatory approval or been assigned any brand names. Its primary therapeutic area is anticoagulation, with potential indications related to the prevention or treatment of thromboembolic disorders[2][4][1].

Other names: CKD-344CKD344CKD 344

Targets

F10 (Factor Xa)

Beyond the preview

Go deeper on CKD-344.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CKD-344.

Explore the full profile